PSMA7

Proteasome subunit alpha type-7 · O14818 · PSMA7 on Sugi Atlas →

24,009 patent compounds predicted against PSMA7, 16,556 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL605949 SCHEMBL605949 0.54 15/20
SCHEMBL607010 SCHEMBL607010 0.56 12/20
SCHEMBL609327 SCHEMBL609327 0.55 12/20
SCHEMBL607553 SCHEMBL607553 0.54 12/20
SCHEMBL606932 SCHEMBL606932 0.53 12/20
SCHEMBL608381 SCHEMBL608381 0.53 12/20
SCHEMBL609081 SCHEMBL609081 0.52 12/20
SCHEMBL606926 SCHEMBL606926 0.52 12/20
SCHEMBL606344 SCHEMBL606344 0.51 12/20
SCHEMBL606616 SCHEMBL606616 0.51 12/20
SCHEMBL1327404 SCHEMBL1327404 0.50 12/20
SCHEMBL607035 SCHEMBL607035 0.61 11/20
SCHEMBL609733 SCHEMBL609733 0.60 11/20
SCHEMBL609324 SCHEMBL609324 0.60 11/20
SCHEMBL605158 SCHEMBL605158 0.59 11/20
SCHEMBL606315 SCHEMBL606315 0.59 11/20
SCHEMBL609290 SCHEMBL609290 0.57 11/20
SCHEMBL607972 SCHEMBL607972 0.55 11/20
SCHEMBL608782 SCHEMBL608782 0.54 11/20
SCHEMBL609278 SCHEMBL609278 0.54 11/20

Clinical trials — most relevant to PSMA7 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Evaluation of the Change in PSMA Expression in Prostate Cancer in Response to Hormonal Therapy PHASE4RECRUITING
Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy PHASE2/PHASE3RECRUITING
Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC PHASE3RECRUITING
Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders) PHASE3RECRUITING
Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer PHASE3COMPLETED
The Effect of Roxadustat on Renal Oxygenation in Diabetes Nephropathy PHASE2NOT_YET_RECRUITING
Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function PHASE2ACTIVE_NOT_RECRUITING
177Lu-PSMA, Niraparib/AA Plus Prednisone for Prostate Cancer PHASE1/PHASE2WITHDRAWN
PS-341 Followed by Removal of Prostate for Those With Prostate Cancer PHASE2COMPLETED
Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer in Japan PHASE2COMPLETED
Desferal Administration to Improve the Impaired Reaction to Hypoxia in Diabetes PHASE2UNKNOWN
Study of Re-treatment With [177Lu]Lu-PSMA in Men With Metastatic Castration Resistance Prostate Cancer PHASE2RECRUITING
A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) PHASE2ACTIVE_NOT_RECRUITING
Phase II Study of Vandetanib in Individuals With Kidney Cancer PHASE2COMPLETED
Phase I/II Study Evaluating PSMA Targeted Radionuclide Therapy in Adult Patients With Metastatic Clear Cell Renal Cancer PHASE1/PHASE2COMPLETED
Cabazitaxel +/- Carboplatin vs 177Lu-PSMA-617 in Metastatic Castrate-resistant Prostate Cancer PHASE2RECRUITING
A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study PHASE1RECRUITING
CTT1057, a Small Molecular Inhibitor of PSMA, as a Novel Imaging Agent of Neovascularization in Renal Cell Carcinoma PHASE1COMPLETED
A Trial of CTT1403 for Metastatic Castration Resistant Prostate Cancer PHASE1COMPLETED
A Phase 1 Trial for Evaluation of the Safety, Pharmacokinetics, and [18F] Radiation Dosimetry of CTT1057 PHASE1COMPLETED
Study of Patients With Stage IV Malignant Melanoma Using PS-341 (Bortezomib, Velcade) and Interferon-alpha-2b in Malignant Melanoma PHASE1COMPLETED
Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Brain Cancer PHASE1COMPLETED
Lu177-EB-PSMA617 Radionuclide Treatment in Patients With Metastatic Castration-resistant Prostate Cancer PHASE1UNKNOWN
Study of 177Lu-PSMA-0057 in Metastatic Prostate Cancer EARLY_PHASE1UNKNOWN
Evaluation of Proteasome as a Marker of Hepatocellular Carcinoma in Cirrhotic Patients Following Curative Treatment nanUNKNOWN
177Lu-PSMA-617 Managed Access Program for mCRPC Patients nanNO_LONGER_AVAILABLE
Low Dose Melphalan and Bortezomib for AML and High-Risk MDS nanCOMPLETED
Cardiovascular Complications of Carfilzomib Treatment nanUNKNOWN
Head-to-head Comparison of 68Ga-PSMA-11 and 18F-PSMA-1007 nanCOMPLETED
Impact of Body Composition on Dosimetry of 177Lu-PSMA Radioligand Therapy nanNOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a PSMA7 binder may also engage these)

ProteinNameSimilarity
Q9Z2U0 1.000 Q9Z2U0 →
Q3ZBG0 1.000 Q3ZBG0 →
Q9PVQ1 1.000 Q9PVQ1 →
Q5RDH8 1.000 Q5RDH8 →
O13268 1.000 O13268 →
Q9PVY6 1.000 Q9PVY6 →
Q9CWH6 1.000 Q9CWH6 →
Q9PTW9 1.000 Q9PTW9 →
PSMA8 Proteasome subunit alpha-type 8 (Proteasome a 1.000 landscape →
O16811 1.000 O16811 →
Q4R7D9 1.000 Q4R7D9 →
O24616 1.000 O24616 →
P48004 1.000 P48004 →
Q0J006 1.000 Q0J006 →
P22769 1.000 P22769 →
A2YXU2 1.000 A2YXU2 →
A2Z3I9 1.000 A2Z3I9 →
Q6YT00 1.000 Q6YT00 →
P30186 1.000 P30186 →
P40303 1.000 P40303 →
Q9XZJ4 0.998 Q9XZJ4 →
O24030 0.998 O24030 →
P18422 0.997 P18422 →
P21243 0.997 P21243 →
Q24178 0.997 Q24178 →
Q95005 0.997 Q95005 →
Q9SXU1 0.996 Q9SXU1 →
Q10329 0.996 Q10329 →
P34120 0.996 P34120 →
O94517 0.996 O94517 →